RRA-12037, Risperidone breast cancer study - Taiwan

Study identification

• EU PAS number:
  EUPAS20969
• Study ID:
  23216
• Official title and acronym:
  RRA-12037, Risperidone breast cancer study - Taiwan
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Kaohsiung Municipal Kai-Syuan Psychiatric Hospital

Study timelines

Date when funding contract was signed

Actual:20/04/2015

Study start date

Actual:04/06/2013

Date of final study report

Actual:31/03/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Janssen R&D

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)